Pregled bibliografske jedinice broj: 1251760
Prevalence of Aminotransferase Macroenzymes in Rheumatoid Arthritis Patients and Impact on Their Management
Prevalence of Aminotransferase Macroenzymes in Rheumatoid Arthritis Patients and Impact on Their Management // eJIFCC : ejournal International Federation of Clinical Chemistry and Laboratory Medicine, 32 (2021), 2; 280-285 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1251760 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Prevalence of Aminotransferase Macroenzymes in
Rheumatoid Arthritis Patients and Impact on Their
Management
Autori
Šimac, Maja ; Šimac, Daniel Victor ; Bilić Zulle, Lidija
Izvornik
EJIFCC : ejournal International Federation of Clinical Chemistry and Laboratory Medicine (1650-3414) 32
(2021), 2;
280-285
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
drug toxicity ; laboratory techniques ; macroenzymes ; rheumatoid arthritis
Sažetak
Introduction: Rheumatoid arthritis (RA) treatment can be hepatotoxic, but liver enzymes can be falsely elevated due to macroenzyme presence. Macroenzymes are often found in autoimmune diseases, but prevalence and effect on treatment is unclear. This study aimed to determine aminotransferase macroenzyme prevalence and effect in RA patients. Materials and methods: This study included consecutive RA patients without liver disease sent for laboratory tests. Samples with elevated AST or ALT were processed for macroenzymes. Presence was determined using polyethylene glycol precipitation (PEG). Results: Out of 126 patients, 21 had elevated aminotransferase levels. Due to liver disease, 6 patients were excluded, another 3 were unavailable for informed consent, leaving 12 patients for inclusion. Out of 12 patients, 1 had increased AST levels, 2 increased ALT levels, and 9 both. Macro- ALT was detected in 5/11 patients, 1 also had macro-AST. Out of 5 patients with macroenzymes, treatment change was seen in 3/5 patients, imaging in 2/5, both in 2/5. Conclusion: Elevated liver enzymes in RA patients is not always indicative of hepatotoxicity, as shown by the fact that about half of patients in our study had macroenzymes detected. Before assuming drug hepatotoxicity and changing treatment or ordering imaging, rheumatologists could consider macroenzyme presence.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Profili:
Lidija Bilić-Zulle
(autor)